Nafarelin

證據等級: L5

預測適應症: 10 個

Nafarelin: From No Registered Indication to Ambras Type Hypertrichosis Universalis Congenita (Predicted)

One-Sentence Summary

Nafarelin is not currently marketed in this jurisdiction, and this evidence pack contains no record of its original approved indication or mechanism of action. The TxGNN model’s top-ranked prediction is Ambras Type Hypertrichosis Universalis Congenita, but this is supported by zero clinical trials and zero publications, and the evidence pack’s own mechanistic assessment flags it as a likely false-positive artefact of embedding similarity rather than a real biological signal.

Quick Overview

Item	Content
Original Indication	Not available — no registered licenses or indication records in this evidence pack
Predicted New Indication	Ambras Type Hypertrichosis Universalis Congenita
TxGNN Prediction Score	99.87%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack, and no original indication is on record — the drug has no licenses and is not currently marketed here, so its established clinical use cannot be verified from this dataset.

More importantly, the evidence pack’s own rationale for this specific prediction states there is no known pathophysiological link between Ambras syndrome (a rare congenital hypertrichosis caused by chromosome 8q rearrangement) and GnRH-axis signalling. The prediction appears to be driven purely by TxGNN’s knowledge-graph embedding similarity, with no supporting trial or literature evidence identified in searches of ClinicalTrials.gov, ICTRP, or PubMed.

For context, this evidence pack does contain lower-ranked predictions with somewhat stronger biological plausibility (e.g. central precocious puberty at rank 9, and pain related to physiological sexual dysfunction at rank 6, discussed below in “Conclusion and Next Steps”), but these are outside the scope of this report, which is structured around the top-ranked candidate only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

No ARTG entries — Nafarelin currently has no registered product licenses (market status: not marketed).

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical trial or literature evidence for Ambras Type Hypertrichosis Universalis Congenita, and the mechanistic analysis included in this evidence pack itself assesses the prediction as biologically implausible — most likely a text/semantic false-positive from the model rather than a genuine repurposing signal.

To proceed, the following is needed:

Confirmed mechanism of action and original approved indication for Nafarelin (currently absent from this dataset)
TFDA/TGA-equivalent product information, including warnings and contraindications (flagged as a Blocking data gap in this evidence pack)
If pursued, at minimum preclinical/mechanistic rationale connecting GnRH-axis modulation to hypertrichosis pathophysiology, followed by case-level or observational evidence before any trial design
Separately worth noting: two other predictions in this dataset carry materially stronger mechanistic grounding — central precocious puberty (rank 9, L4, consistent with Nafarelin’s known GnRH-agonist pharmacology) and physiological sexual disorder via endometriosis-related pain (rank 6, L3, one supporting RCT) — these may warrant their own dedicated evaluation rather than being screened out by this report’s focus on the top-ranked candidate.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.